Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the non-inferiority of QVA149 110/50 µg qd as compared to concurrent administration of QAB149 150 µg qd plus NVA237 50 µg qd in terms of its effect on trough FEV1 (mean of 23 h 15 min and 23 h 45 min post-dose) following 28 days of blinded treatment in patients with moderate to severe chronic obstructive pulmonary disease.
Critère d'inclusion
- Chronic Obstructive Pulmonary Disease (COPD)